Nu Skin Enterprises (NUS) investor relations material

Executive summary

• Q2 2026 revenue was $320.1 million, down 17.1% year-over-year, with a $4 million negative FX impact and supported by Prysm iO rollout and operational efficiency.

• Adjusted EPS was $0.20, excluding non-cash impairment and tax charges, compared to $0.43 last year; reported EPS was $(5.14) due to significant non-cash charges.

• Customer count declined 14% to 660,037; paid affiliates and sales leaders decreased 8% and 9% year-over-year.

• Strategic priorities include expanding anti-aging leadership, empowering sales force, Prysm iO rollout, and India market launch delayed to H1 2027 for business model optimization.

Financial highlights

• Gross margin was 68.2% (down from 68.8% YoY); adjusted operating margin was 6.1% (vs. 8% prior year); GAAP operating margin was -18.5%.

• Net loss was $249.8 million, or $(5.14) per share; adjusted net income was $9.95 million, or $0.20 per share.

• Operating cash flow was $10.6 million in Q2; cash and equivalents at quarter-end were $189.6 million; total debt was $213.7 million.

• Dividend payments totaled $2.9 million in Q2; $137.3 million remains authorized for share repurchases, but none executed in Q2.

Outlook and guidance

• Q3 2026 revenue expected at $310–$340 million, down 15% to 7% year-over-year, with a 2–3% FX headwind; Q3 adjusted EPS guidance is $0.10–$0.20.

• Full-year 2026 revenue guidance is $1.28–$1.35 billion, down 14% to 9% year-over-year; adjusted EPS expected between $0.70 and $0.90.

• Guidance excludes non-cash charges and transition costs; effective tax rate expected at ~35%.

• India market launch delayed to H1 2027 to optimize business model and operational readiness.